FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024556650> ?p ?o ?g. }

• W2024556650 endingPage "306" @default.
• W2024556650 startingPage "295" @default.
• W2024556650 abstract "Objective: To define the pharmacokinetic behaviour of cefepime in neonates with severe nosocomial infections using a mixed effects model. Patients and methods: Thirty-one newborn infants were included in the study; 10 additional infants participated in the validation of the pharmacokinetic model. Cefepime CL and V were determined using an open monocompartmental model with first-order elimination. The influence of demographic and clinical characteristics on the model was evaluated. The non-linear mixed effect model (nonmem) program was used to determine the pharmacokinetic population model. Results: The mean corrected gestational age for infants participating in the construction and validation of the model were 35 and 33 weeks, respectively. Factors included in the final pharmacokinetic model were body surface area (BSA) and calculated CLCR. The final population model was CL (L/h) = 0·457 BSA (m2) + 0·243 CLCR (L/h) and V(L) = 4·12 BSA (m2). This model explains 33·3% of the interindividual variability for CL and 12·8% for V. This model was validated in ten neonates with nosocomial infections by assessing the predictive capacity of plasma cefepime concentrations using a priori and Bayesian strategies. Conclusions: The predictive performance of this population model for cefepime plasma concentrations was adequate for clinical purposes and can be used for individualizing cefepime therapy in newborn infants with severe infections. Cefepime plasma concentrations can be predicted based on BSA and calculated CLCR. Cefepime therapy using a 250 mg/m2 dose administered every 12 h is adequate to achieve plasma concentrations greater than 8 μg/mL during more than 60% of the dosing interval and is expected to be effective in the treatment of bloodstream infections caused by most gram negative organisms in newborn infants. A dose of 550 mg/m2 would be required for the treatment of infections caused by Pseudomonas sp." @default.
• W2024556650 created "2016-06-24" @default.
• W2024556650 creator A5002632050 @default.
• W2024556650 creator A5010165860 @default.
• W2024556650 creator A5036597760 @default.
• W2024556650 creator A5058112895 @default.
• W2024556650 creator A5063183787 @default.
• W2024556650 creator A5082047647 @default.
• W2024556650 creator A5087083823 @default.
• W2024556650 date "2008-06-01" @default.
• W2024556650 modified "2023-10-02" @default.
• W2024556650 title "Population pharmacokinetics of cefepime in neonates with severe nosocomial infections" @default.
• W2024556650 cites W1573668492 @default.
• W2024556650 cites W1972750978 @default.
• W2024556650 cites W2003143162 @default.
• W2024556650 cites W2012436282 @default.
• W2024556650 cites W2018345158 @default.
• W2024556650 cites W2032462589 @default.
• W2024556650 cites W2046526279 @default.
• W2024556650 cites W2048073199 @default.
• W2024556650 cites W2063576651 @default.
• W2024556650 cites W2066464642 @default.
• W2024556650 cites W2092418356 @default.
• W2024556650 cites W2108184047 @default.
• W2024556650 cites W2109318040 @default.
• W2024556650 cites W2113717321 @default.
• W2024556650 cites W2129085875 @default.
• W2024556650 cites W2133844533 @default.
• W2024556650 cites W2159272981 @default.
• W2024556650 cites W2163689770 @default.
• W2024556650 cites W2171697855 @default.
• W2024556650 cites W3026204017 @default.
• W2024556650 cites W4233931284 @default.
• W2024556650 doi "https://doi.org/10.1111/j.1365-2710.2008.00913.x" @default.
• W2024556650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18452417" @default.
• W2024556650 hasPublicationYear "2008" @default.
• W2024556650 type Work @default.
• W2024556650 sameAs 2024556650 @default.
• W2024556650 citedByCount "24" @default.
• W2024556650 countsByYear W20245566502012 @default.
• W2024556650 countsByYear W20245566502013 @default.
• W2024556650 countsByYear W20245566502014 @default.
• W2024556650 countsByYear W20245566502016 @default.
• W2024556650 countsByYear W20245566502017 @default.
• W2024556650 countsByYear W20245566502018 @default.
• W2024556650 countsByYear W20245566502019 @default.
• W2024556650 countsByYear W20245566502020 @default.
• W2024556650 countsByYear W20245566502021 @default.
• W2024556650 countsByYear W20245566502022 @default.
• W2024556650 countsByYear W20245566502023 @default.
• W2024556650 crossrefType "journal-article" @default.
• W2024556650 hasAuthorship W2024556650A5002632050 @default.
• W2024556650 hasAuthorship W2024556650A5010165860 @default.
• W2024556650 hasAuthorship W2024556650A5036597760 @default.
• W2024556650 hasAuthorship W2024556650A5058112895 @default.
• W2024556650 hasAuthorship W2024556650A5063183787 @default.
• W2024556650 hasAuthorship W2024556650A5082047647 @default.
• W2024556650 hasAuthorship W2024556650A5087083823 @default.
• W2024556650 hasBestOaLocation W20245566501 @default.
• W2024556650 hasConcept C112705442 @default.
• W2024556650 hasConcept C187212893 @default.
• W2024556650 hasConcept C2776239304 @default.
• W2024556650 hasConcept C2777050379 @default.
• W2024556650 hasConcept C2779631663 @default.
• W2024556650 hasConcept C2780272996 @default.
• W2024556650 hasConcept C2908647359 @default.
• W2024556650 hasConcept C3020755252 @default.
• W2024556650 hasConcept C501593827 @default.
• W2024556650 hasConcept C71924100 @default.
• W2024556650 hasConcept C86803240 @default.
• W2024556650 hasConcept C89423630 @default.
• W2024556650 hasConcept C94665300 @default.
• W2024556650 hasConcept C98274493 @default.
• W2024556650 hasConcept C99454951 @default.
• W2024556650 hasConceptScore W2024556650C112705442 @default.
• W2024556650 hasConceptScore W2024556650C187212893 @default.
• W2024556650 hasConceptScore W2024556650C2776239304 @default.
• W2024556650 hasConceptScore W2024556650C2777050379 @default.
• W2024556650 hasConceptScore W2024556650C2779631663 @default.
• W2024556650 hasConceptScore W2024556650C2780272996 @default.
• W2024556650 hasConceptScore W2024556650C2908647359 @default.
• W2024556650 hasConceptScore W2024556650C3020755252 @default.
• W2024556650 hasConceptScore W2024556650C501593827 @default.
• W2024556650 hasConceptScore W2024556650C71924100 @default.
• W2024556650 hasConceptScore W2024556650C86803240 @default.
• W2024556650 hasConceptScore W2024556650C89423630 @default.
• W2024556650 hasConceptScore W2024556650C94665300 @default.
• W2024556650 hasConceptScore W2024556650C98274493 @default.
• W2024556650 hasConceptScore W2024556650C99454951 @default.
• W2024556650 hasIssue "3" @default.
• W2024556650 hasLocation W20245566501 @default.
• W2024556650 hasLocation W20245566502 @default.
• W2024556650 hasOpenAccess W2024556650 @default.
• W2024556650 hasPrimaryLocation W20245566501 @default.
• W2024556650 hasRelatedWork W1987821107 @default.
• W2024556650 hasRelatedWork W2009939288 @default.
• W2024556650 hasRelatedWork W2024556650 @default.
• W2024556650 hasRelatedWork W2031104234 @default.

• next